Joseph Zakrzewski, executive chairman, Amarin

pharmafile | January 13, 2010 | Appointment | Research and Development Amarin, appointment, research and development 

Dublin-headquartered biotech Amarin has appointed Joseph Zakrzewski executive chairman.

He is currently the chief executive of Xcellerex, a Massachusetts-based biotechnology company, and serves on the board of directors of Insulet Corporation and is chairman of the boards of directors for Promedior and Zelos Therapeutics.

Zakrzewski has more than 20 years of industry experience, including making significant contributions to Reliant Pharmaceuticals as chief operating officer in the lead up to its 2007 acquisition by GlaxoSmithKline.

He has also spent 17 years at Lilly in a variety of roles, including VP of corporate business development where he had global responsibility for licensing activities.

Commenting on his appointment Zakrzewski said: “Having reviewed Amarin’s compelling business plan and cardiovascular development strategy, I am pleased to be joining the company’s board of directors as executive chairman.

“With AMR101 poised to enter phase III clinical trials, and the combination of the company’s recent financing by top-tier investors, the composition of its board and the high quality management team, I believe this is a unique opportunity to create value for Amarin shareholders.”

Previous chairman Thomas Lynch will continue to serve as a member of Amarin’s board of directors.

Related Content

medications-money-cure-tablets

Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain

Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of …

EMA grants marketing authorisation for Amarin’s heart attack treatment

Amarin have been granted authorisation from the EMA to market a treatment that will reduce …

fda2outsideweb

Label expansion of Amarin’s Vascepa has unanimous backing of FDA advisory panel

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted in favour of expanding …

Latest content